<code id='1D7FA62F19'></code><style id='1D7FA62F19'></style>
    • <acronym id='1D7FA62F19'></acronym>
      <center id='1D7FA62F19'><center id='1D7FA62F19'><tfoot id='1D7FA62F19'></tfoot></center><abbr id='1D7FA62F19'><dir id='1D7FA62F19'><tfoot id='1D7FA62F19'></tfoot><noframes id='1D7FA62F19'>

    • <optgroup id='1D7FA62F19'><strike id='1D7FA62F19'><sup id='1D7FA62F19'></sup></strike><code id='1D7FA62F19'></code></optgroup>
        1. <b id='1D7FA62F19'><label id='1D7FA62F19'><select id='1D7FA62F19'><dt id='1D7FA62F19'><span id='1D7FA62F19'></span></dt></select></label></b><u id='1D7FA62F19'></u>
          <i id='1D7FA62F19'><strike id='1D7FA62F19'><tt id='1D7FA62F19'><pre id='1D7FA62F19'></pre></tt></strike></i>

          Home / hotspot / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:771
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images

          LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

          That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

          advertisement

          “We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In